Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Cash from Operations (2024 - 2025)

Kairos Pharma's Cash from Operations history spans 2 years, with the latest figure at 805000.0 for Q2 2025.

  • For Q2 2025, Cash from Operations fell 379.17% year-over-year to 805000.0; the TTM value through Jun 2025 reached 5342000.0, changed N/A, while the annual FY2025 figure was 3441000.0, 13.0% up from the prior year.
  • Cash from Operations reached 805000.0 in Q2 2025 per KAPA's latest filing, down from 714000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 36000.0 in Q1 2024 to a low of 2020000.0 in Q3 2024.